How Do CDMOs Scale High-Concentration Biologic Formulations?ByRyan Swanson,Zachary ZubulakeAugust 21st 2026
GSDIa Gene Therapy Approval Signals New Path for Rare Disease ManufacturingByZachary ZubulakeAugust 20th 2026
Ask the Expert: Complying with StandardsBySusan J. Schniepp,Siegfried Schmitt,Susan HaigneyAugust 20th 2026